title: [Dissociation between the effect on myeloblastoma and the hematologic effect of Ara-C therapy: report of an autopsied myeloblastic leukemia case with around five-year course].
authors.forename: T
authors.initials: T
authors.lastname: Koyama
authors.forename: S
authors.initials: S
authors.lastname: Tohda
authors.forename: T
authors.initials: T
authors.lastname: Kamiyama
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Nagata
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: O
authors.initials: O
authors.lastname: Miura
authors.forename: Y
authors.initials: Y
authors.lastname: Maruyama
authors.forename: A
authors.initials: A
authors.lastname: Kato
authors.forename: N
authors.initials: N
authors.lastname: Murakami
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology; D003630:Daunorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D012074:Remission Induction; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy
chemical_list: D003561:Cytarabine; D015122:Mercaptopurine; D003630:Daunorubicin